• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微流控平台与批量混合平台在合成无定形药物-多糖纳米颗粒复合物中的直接比较。

Direct comparison between millifluidic and bulk-mixing platform in the synthesis of amorphous drug-polysaccharide nanoparticle complex.

作者信息

Dong Bingxue, Hadinoto Kunn

机构信息

School of Chemical and Biomedical Engineering, Nanyang Technological University, 637459, Singapore.

School of Chemical and Biomedical Engineering, Nanyang Technological University, 637459, Singapore.

出版信息

Int J Pharm. 2017 May 15;523(1):42-51. doi: 10.1016/j.ijpharm.2017.03.021. Epub 2017 Mar 19.

DOI:10.1016/j.ijpharm.2017.03.021
PMID:28323097
Abstract

Amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex) had emerged as an ideal supersaturating delivery system of poorly-soluble drugs attributed to its many attractive characteristics. Herein we presented for the first time direct comparison between two nanoplex synthesis platforms, i.e. millifluidics and bulk mixing, representing continuous and batch production modes, respectively. They were compared by the resultant nanoplex's (1) physical characteristics (size, zeta potential, and payload), (2) preparation efficiency, (3) storage stability, (4) dissolution rate/supersaturation generation, and (5) production consistency. The effects of key variables in drug-polysaccharide complexation (pH, charge ratio) were investigated in both platforms. Perphenazine and dextran sulfate were used as the drug and polysaccharide models, respectively. The results showed that both platforms shared similar dependences on pH and charge ratio with similar optimal preparation conditions, where the pH was the governing variable through its influence on size and zeta potential, Nanoplexes having mostly similar characteristics (size ≈70-90nm, zeta potential ≈-50mV) were produced by both platforms, except for the payload where bulk mixing resulted in lower payload (65% versus 85%). The lower payload, however, resulted in its superior supersaturation generation. Nevertheless, millifluidics was favored attributed to its superior production consistency and scalability.

摘要

无定形药物 - 多糖纳米颗粒复合物(或药物纳米复合物)因其诸多吸引人的特性,已成为难溶性药物理想的过饱和递送系统。在此,我们首次对两种纳米复合物合成平台进行了直接比较,即微流控和批量混合,它们分别代表连续和间歇生产模式。通过所得纳米复合物的以下方面对它们进行比较:(1)物理特性(尺寸、zeta电位和载药量),(2)制备效率,(3)储存稳定性,(4)溶解速率/过饱和生成,以及(5)生产一致性。在两个平台上均研究了药物 - 多糖络合过程中关键变量(pH值、电荷比)的影响。分别使用奋乃静和硫酸葡聚糖作为药物和多糖模型。结果表明,两个平台对pH值和电荷比具有相似的依赖性,且具有相似的最佳制备条件,其中pH值通过对尺寸和zeta电位的影响而成为主导变量。两个平台制备的纳米复合物大多具有相似的特性(尺寸≈70 - 90nm,zeta电位≈ - 50mV),但批量混合制备的纳米复合物载药量较低(65%对85%)。然而,较低的载药量导致其过饱和生成能力更强。尽管如此,微流控因其卓越的生产一致性和可扩展性而更受青睐。

相似文献

1
Direct comparison between millifluidic and bulk-mixing platform in the synthesis of amorphous drug-polysaccharide nanoparticle complex.微流控平台与批量混合平台在合成无定形药物-多糖纳米颗粒复合物中的直接比较。
Int J Pharm. 2017 May 15;523(1):42-51. doi: 10.1016/j.ijpharm.2017.03.021. Epub 2017 Mar 19.
2
Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine.奋乃静与硫酸葡聚糖的无定形纳米颗粒复合物作为抗精神病药物奋乃静的一种新的溶解度增强策略。
Drug Dev Ind Pharm. 2017 Jun;43(6):996-1002. doi: 10.1080/03639045.2017.1287721. Epub 2017 Feb 13.
3
Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applications.用于过饱和药物递送应用的尺寸可调的无定形药物-多糖纳米颗粒复合物的微流控合成。
Eur J Pharm Biopharm. 2017 Mar;112:196-203. doi: 10.1016/j.ejpb.2016.11.030. Epub 2016 Nov 27.
4
Enhancing the physical stability and supersaturation generation of amorphous drug-polyelectrolyte nanoparticle complex via incorporation of crystallization inhibitor at the nanoparticle formation step: A case of HPMC versus PVP.通过在纳米颗粒形成步骤中加入结晶抑制剂来增强无定形药物-聚电解质纳米颗粒复合物的物理稳定性和过饱和度生成:以 HPMC 与 PVP 为例。
Eur J Pharm Sci. 2019 Oct 1;138:105035. doi: 10.1016/j.ejps.2019.105035. Epub 2019 Aug 3.
5
Carboxymethyl cellulose is a superior polyanion to dextran sulfate in stabilizing and enhancing the solubility of amorphous drug-polyelectrolyte nanoparticle complex.羧甲基纤维素是一种优于硫酸葡聚糖的聚阴离子,可稳定并提高无定形药物-聚电解质纳米粒子复合物的溶解度。
Int J Biol Macromol. 2019 Oct 15;139:500-508. doi: 10.1016/j.ijbiomac.2019.08.023. Epub 2019 Aug 3.
6
A new bioavailability enhancement strategy of curcumin via self-assembly nano-complexation of curcumin and bovine serum albumin.一种通过姜黄素与牛血清白蛋白自组装纳米络合提高姜黄素生物利用度的新策略。
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:25-33. doi: 10.1016/j.msec.2017.02.018. Epub 2017 Feb 10.
7
A supersaturating delivery system of silibinin exhibiting high payload achieved by amorphous nano-complexation with chitosan.一种通过与壳聚糖形成无定形纳米络合物实现高载药量的水飞蓟宾过饱和递送系统。
Eur J Pharm Sci. 2016 Jun 30;89:163-71. doi: 10.1016/j.ejps.2016.04.036. Epub 2016 Apr 30.
8
Cost-effective alternative to nano-encapsulation: Amorphous curcumin-chitosan nanoparticle complex exhibiting high payload and supersaturation generation.纳米封装的经济高效替代方案:具有高载药量和超饱和生成特性的无定形姜黄素-壳聚糖纳米颗粒复合物
Eur J Pharm Biopharm. 2015 Oct;96:1-10. doi: 10.1016/j.ejpb.2015.07.007. Epub 2015 Jul 10.
9
Combining inkjet printing and amorphous nanonization to prepare personalized dosage forms of poorly-soluble drugs.结合喷墨打印和无定形纳米化制备难溶性药物的个性化剂型。
Eur J Pharm Biopharm. 2015 Oct;96:314-21. doi: 10.1016/j.ejpb.2015.08.012. Epub 2015 Aug 29.
10
Effects of chitosan molecular weight on the physical and dissolution characteristics of amorphous curcumin-chitosan nanoparticle complex.壳聚糖分子量对无定形姜黄素-壳聚糖纳米颗粒复合物物理及溶解特性的影响
Drug Dev Ind Pharm. 2018 Jan;44(1):82-88. doi: 10.1080/03639045.2017.1373802. Epub 2017 Sep 11.

引用本文的文献

1
A review on the green and sustainable synthesis of silver nanoparticles and one-dimensional silver nanostructures.银纳米颗粒和一维银纳米结构的绿色可持续合成综述
Beilstein J Nanotechnol. 2021 Jan 25;12:102-136. doi: 10.3762/bjnano.12.9. eCollection 2021.
2
Sources, Extraction and Biomedical Properties of Polysaccharides.多糖的来源、提取及生物医学特性
Foods. 2019 Aug 1;8(8):304. doi: 10.3390/foods8080304.
3
The Microfluidic Technique and the Manufacturing of Polysaccharide Nanoparticles.微流控技术与多糖纳米颗粒的制造
Pharmaceutics. 2018 Dec 9;10(4):267. doi: 10.3390/pharmaceutics10040267.